2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 449

Pain Processing in Chronic Low Back Pain Individuals with or without Sick Leave
Abstract Number: 945

Pain, Functional Limitations and Physical Activity Participation Trajectories in Patients with Symptomatic Knee and Hip Osteoarthritis: A Multi-Trajectory Analysis
Abstract Number: 1428

Parental Involvement and Adolescents/Young Adults Self-Management during the Transition Period: A Cross-Sectional Survey in Childhood Onset Rheumatic Diseases
Abstract Number: 1030

Parenteral Injection of Human Adipose-Derived Mesenchymal Stem Cells Attenuates Inflammation in an Acute Model of Gouty Arthritis
Abstract Number: 187

Participant-Reported Effect of an Indigenous Health Continuous Professional Development Education Initiative
Abstract Number: 446

Participation in American Football Is Associated with Increased Risk for Knee Pain and Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 1853

Paternal Use of Methotrexate (MTX) and Congenital Malformations – a Systematic Review and Meta-Analysis
Abstract Number: 1902

Pathogenic and Therapeutic Modulation of Activating Epigenetic Memory at a Novel Enhancer for TGFβ2 in Systemic Sclerosis
Abstract Number: 1587

Pathogenic Role of Interleukin 27 in the Nonobese Diabetic Mouse Model of Sjögren Syndrome
Abstract Number: 2077

Pathological Osteogenesis and Inflammation in Experimental Spondyloarthritis Are Associated with Aberrant Type H Blood Vessels and Development of High Endothelial Venules Accompanied By Ectopic Lymphoid Structures in Bone Marrow
Abstract Number: 1892

Patient and Health System Characteristics Associated with Receipt of Disease Modifying Anti-Rheumatic Drugs in a National VA Sample
Abstract Number: 1519

Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Abstract Number: 2723

Patient Experience in ANCA-Associated Vasculitis Evolves over Time from Diagnosis and Both Benefits and Adverse Impacts Are Felt with Current Therapy
Abstract Number: 442

Patient Factors Associated with Gaps in Osteoarthritis Care
Abstract Number: 2368

Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].